Ducentis BioTherapeutics

About:

Ducentis is a pre-clinical stage company that aims to develop novel therapies for inflammation and autoimmune disease.

Website: http://ducentisbio.com/

Top Investors: Capital Cell, Oxford Technology Management

Description:

Ducentis is a pre-clinical stage company aiming to develop novel therapies for inflammation and autoimmune disease. Ducentis' target is the CD200/CD200R axis which imparts a deactivating signal to activated immune cells in both the innate and adaptive arms of the immune system. Potential therapeutic targets include transplant rejection and autoimmune and inflammatory diseases affecting the lungs, liver, kidney, eye, bone, and cartilage.